NAV

Medifoxamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Medifoxamine
DrugBank Accession Number
DB13219
Background

Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity 2,1.

Type
Small Molecule
Groups
Approved
Structure
3D
Similar Structures
Weight
Average: 257.333
Monoisotopic: 257.141578856
Chemical Formula
C16H19NO2
Synonyms
  • Medifoxamine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Medifoxamine.
AcenocoumarolThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Acenocoumarol.
AcetazolamideThe risk or severity of CNS depression can be increased when Acetazolamide is combined with Medifoxamine.
AcetophenazineThe risk or severity of CNS depression can be increased when Acetophenazine is combined with Medifoxamine.
AgomelatineThe risk or severity of CNS depression can be increased when Agomelatine is combined with Medifoxamine.
Food Interactions
Not Available

Categories

ATC Codes
N06AX13 — Medifoxamine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Trialkylamines / Acetals / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Acetal / Amine / Aromatic homomonocyclic compound / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
KWU7C2A1NT
CAS number
32359-34-5
InChI Key
QNMGHBMGNRQPNL-UHFFFAOYSA-N
InChI
InChI=1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3
IUPAC Name
(2,2-diphenoxyethyl)dimethylamine
SMILES
CN(C)CC(OC1=CC=CC=C1)OC1=CC=CC=C1

References

General References
  1. Mitchell PB: Novel French antidepressants not available in the United States. Psychopharmacol Bull. 1995;31(3):509-19. [Article]
  2. WHO Pharmaceuticals Newsletter 1999, No. 09&12 (1999; 30 pages) [Link]
ChemSpider
33212
RxNav
29434
ChEBI
135061
ChEMBL
CHEMBL85231
ZINC
ZINC000038605999
Wikipedia
Medifoxamine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.327 mg/mLALOGPS
logP3.05ALOGPS
logP3.8Chemaxon
logS-2.9ALOGPS
pKa (Strongest Basic)8.18Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area21.7 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity75.83 m3·mol-1Chemaxon
Polarizability28.21 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0a4i-9000000000-2cff45972d505cf1d074
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-3590000000-f3f7ba005a6f3c804931
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-9600000000-f9e2ece13eb2b51cfc17
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9500000000-daeb8a0027336fe7d71c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-3882ca098140474397bf
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-05xs-9410000000-927267e690f968f5770c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-35abdc9a830075f6b342
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-172.1237904
predicted
DarkChem Lite v0.1.0
[M-H]-155.8484
predicted
DeepCCS 1.0 (2019)
[M+H]+171.5094904
predicted
DarkChem Lite v0.1.0
[M+H]+158.2064
predicted
DeepCCS 1.0 (2019)
[M+Na]+172.0302904
predicted
DarkChem Lite v0.1.0
[M+Na]+164.29956
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:37 / Updated at February 21, 2021 18:54